← Human Trials & Peer-Reviewed Studies
Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Plain-language guide to PMID 20381654 (2010): randomized controlled trial of BNP (Nesiritide) in 206 patients.
Key Facts
- PMID
- 20381654
- Journal
- The American journal of cardiology
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Haeck JD et al. (11 authors)
- DOI
- 10.1016/j.amjcard.2009.12.003
What This Study Did, in Plain Language
What Was Tested
Researchers studied BNP (Nesiritide) in this randomized controlled trial publication.
The purpose of the present study was to determine the prognostic value of N-terminal pro-brain natriuretic peptide (NT-pro-BNP), among other serum biomarkers, on cardiac magnetic resonance (CMR) imaging parameters of cardiac function and infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Why It Was Studied
The researchers measured NT-pro-BNP, cardiac troponin T, creatinine kinase-MB fraction, high-sensitivity C-reactive protein, and creatinine on the patients' arrival at the catheterization laboratory in 206 patients with ST-segment elevation myocardial infarction.
The NT-pro-BNP levels were divided into quartiles and correlated with left ventricular function and infarct size measured by CMR imaging at 4 to 6 months.
Who Took Part
The study group was 206 patients.
By PubMed's age tags, the people studied were middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized study.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
What Was Measured
The researchers measured NT-pro-BNP, cardiac troponin T, creatinine kinase-MB fraction, high-sensitivity C-reactive protein, and creatinine on the patients' arrival at the catheterization laboratory in 206 patients with ST-segment elevation myocardial infarction.
The NT-pro-BNP levels were divided into quartiles and correlated with left ventricular function and infarct size measured by CMR imaging at 4 to 6 months.
Topics PubMed links to this paper include Angioplasty, Balloon, Coronary, Anterior Wall Myocardial Infarction, Biomarkers, C-Reactive Protein, Creatine Kinase, BB Form, Electrocardiography and Magnetic Resonance Imaging.
What This Means in Plain Language
The paper is a randomized study of BNP (Nesiritide) in 206 patients.
The publication is from 2010 (The American journal of cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.